ARTICLES BY LOUIS
Can’t Escape Outsourcing Anywhere
I picked up a copy of Fortune to read on the train home. Before we were out of Penn Station, I was already deep into a section titled “Outsourcing for GOOD.” This 12-page spread in Fortune is a “special advertising section,” which means it offers a clear idea of how outsourcing providers in other industries think about themselves and market their services. Would they have a different tact than service providers for drug discovery, development and manufacturing?
Learn Pfizer’s Guiding Principles For Externalization At Outsourced Pharma West
Firelli Alonso-Caplen has been managing outsourcing for 10 years, first at Wyeth and then Pfizer. “The key really is the initial selection process for the CDMO,” she said in a recent conversation regarding our panel at Outsourced Pharma West, in San Francisco, November 10-11.
ONO Pharmaceutical Strives For Global Sales
Gyo Sagara, president, representative director and CEO, challenges his company to enter the cancer field and gain big-pharma relevance.
Puerto Rico Back On The Map Of Pharmaceutical Locations
There were many options (and precious time) for a journalist at BIO 2014 in San Diego: pharmaceuticals, biotechs, academia, countries, regions, consortiums and the like. One place I just had to find: Puerto Rico. Where had the Commonwealth gone? Was it still on the map of pharmaceutical development, manufacturing and outsourcing?
AAIPharma/Cambridge Major: A CDMO With Two Names And A New CEO
Stephan Kutzer took the time to speak to Outsourced Pharma on July 9, the day AAIPharma Services Corp. (AAIPharma) and Cambridge Major Laboratories, Inc. (CML) announced he had become the combined companies’ new CEO.
Give Credit To The U.S. Pharma Industry For Leading Reincorporation
You’ve got to give credit to companies in our industry. If punitive U.S. taxation policy is going to drive them to do deals overseas, they are going to go big-time and in style. If they are not allowed to repatriate global dollars in a sensible manner, they will invest them with fanfare abroad.
Discovery Fast Track At GSK Assists Academia And Adds To The Pipeline
GlaxoSmithKline (GSK), like so many other pharmaceutical and biotechnology companies, is looking to boost its pipeline. Pearl Huang, Ph.D., vice president and global head of GSK’s Discovery Partnerships with Academia (DPAc), is taking direct aim at the drug discovery concept stage to take up the challenge. By Louis Garguilo, Executive Editor, Outsourced Pharma
Fibrotech Knows Translational Research Methodology, Shire and Pharma Industry Agree
Australia-based biotech with anti-fibrosis program designs the best path to clinical success. By Louis Garguilo, Executive Editor, Outsourced Pharma
Fireworks At BIO 2014 San Diego
Aboard USS Midway, San Diego Bay – The late evening sky west of the ship’s deck lights up with fireworks feting the assembled attendees and honorary of the Biotechnology Industry Organization’s 21st annual international conference and exhibition. Bright lights rise meteorically and explode in an array of color and excitement, illustrating visually the enthusiasm and energy of the biotechnology industry gathered on board, and by extension around the world.
Prophet For Progress In Clinical Trial Efficiencies
The hardest part of innovating in business might be having the right market solution but struggling to get full buy-in from customers. To overcome the resistance, innovators have to become prophets of their own convictions. Recently, we met one such “prophet,” Jim Murphy, President, Almac’s Clinical Technologies business unit. Almac Group provides a range of services including research, pharmaceutical and clinical development, clinical trial supply and technology, and commercial packaging and manufacture.
Meeting a “prophet” in Las Vegas might conjure up some interesting images. Murphy was actually spreading the good word when we had the chance to interview him at the 2014 Partnerships In Clinical Trials conference and exhibition in April.